Shaw R W
Royal Free Hospital, London, U.K.
Eur J Obstet Gynecol Reprod Biol. 1988 Jun;28(2):109-16. doi: 10.1016/0028-2243(88)90086-x.
We know that there is a wide range of clinical applications for GnRH analogues in the field of benign gynaecological disorders. As we understand more of the physiology and mechanism of these GnRH agonists, and there appear more varied and perhaps efficient delivery systems, and antagonists become available, it may be possible to develop a graded approach in suppression of the hypothalamic pituitary axis. The true potential of these agents is then yet to be fully realized. There can be no doubt they are going to influence practice dramatically over the next decade. The potency of these agents, perhaps specifically their effects of oestrogen deficiency and calcium bone metabolism, suggests that limitation of duration of use and timing of recurrent administration to individuals is likely to be necessary.
我们知道,促性腺激素释放激素(GnRH)类似物在良性妇科疾病领域有着广泛的临床应用。随着我们对这些GnRH激动剂的生理学和作用机制有了更多了解,出现了更多种类且可能更有效的给药系统,并且拮抗剂也已可用,或许有可能开发出一种分级抑制下丘脑-垂体轴的方法。这些药物的真正潜力尚未完全实现。毫无疑问,它们将在未来十年极大地影响临床实践。这些药物的效力,尤其是它们对雌激素缺乏和钙骨代谢的影响,表明可能有必要限制用药时间以及对个体进行反复给药的时机。